StageSeries D | Alive
Last Raised$27.22M | 7 yrs ago
EyeTechCare is developing non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU), a technology that allows ambulatory and rapid treatment to be performed, thereby limiting the cost and the risk to the patient. The company's first device, EyeOP1 (R), for the treatment of glaucoma, has been undergoing clinical trials in France and Europe.
Missing: EyeTechCare's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: EyeTechCare's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing EyeTechCare
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
EyeTechCare is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest EyeTechCare News
Jan 19, 2021
Disclosures: Stalmans reports consultancies and research grants with and from Aerie, Alcon, Allergan, EyeD Pharma, EyeTechCare, Horus Pharma, Oculis, Santen, Laboratoires Théa and reports non-financial support from Théa Pharma, during the conduct of the study; personal fees from Aerie, Alcon and EyeTechCare; and personal fees and nonfinancial support from Allergan, Santen and Théa Pharma outside the submitted work. Please see the full study for all other authors’ financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio Most patients reported satisfaction with their glaucoma treatment despite a high frequency of ocular signs during ophthalmological exams and symptoms at and between instillations. Researchers published the findings in Clinical Ophthalmology. “To date, patient dissatisfaction with topical glaucoma treatments has only sporadically been studied, and the present study provides new insights in real-life data...,” Ingeborg Stalmans, MD, PhD, department of ophthalmology, Universitair Ziekenhuis Leuven, Belgium, and colleagues wrote. Stalmans and colleagues conducted an observational, multicenter, international, cross-sectional study of 793 patients (51% men; 91.5% received monotherapy) with treated, stabilized glaucoma (95.1% open angle). The outcomes of interest included patient satisfaction; ocular signs including conjunctival hyperemia, ocular surface disease (OSD) and positive conjunctival fluorescein staining; and patient reports of symptoms on and between instillations. Most (93.7%) patients reported they were satisfied or very satisfied with the tolerability of their treatment, but patients also commonly reported symptoms at time of instillation (31.4%) and between instillations (57.3%). The most common symptoms reported at instillation were pain or discomfort (21.2%) and blurred vision (7.2%). The most common symptoms reported between instillations were burning (17.4%), crusts on eyelashes (15.9%), red eye (13.1%), photophobia (12.9%), tingling (12.7%), watering (11.9%), itching (9.2%), foreign body sensation (9.0%) and dry eye sensation (5.4%). “One may hypothesize that a reason for the discrepancy between the high patient satisfaction and the high number of observed tolerance issues may reside, as already highlighted in our previous paper, in the fact that ophthalmologists insist on the importance of controlling IOP , while paying less attention to local intolerability issues,” researchers wrote. “Moreover, ophthalmologists and patients may consider the occurrence of such side effects as ‘the price to pay’ for successfully controlling their glaucoma.” There was also a high frequency of ocular signs during ophthalmological examination, including conjunctival hyperemia (32%), OSD (42.5%) and positive conjunctival fluorescein staining (10.3%). Dissatisfaction was higher among patients who reported symptoms at time of instillation (OR = 3.03) and who used tear substitutes (OR = 4.63). Other factors associated with dissatisfaction included hyperemia, OSD and a positive conjunctival fluorescein staining test (P < .001). “In conclusion, even if patients may be highly satisfied with their current treatment, most of them present [with] ocular signs and symptoms,” researchers wrote. “A treatment change should be considered in case of clinical signs or patient-reported symptoms.” Perspective
EyeTechCare Frequently Asked Questions (FAQ)
When was EyeTechCare founded?
EyeTechCare was founded in 2008.
Where is EyeTechCare's headquarters?
EyeTechCare's headquarters is located at 2871, Avenue de l'Europe, Rillieux-la-Pape.
What is EyeTechCare's latest funding round?
EyeTechCare's latest funding round is Series D.
How much did EyeTechCare raise?
EyeTechCare raised a total of $51.76M.
Who are the investors of EyeTechCare?
Investors of EyeTechCare include Everpine Capital, Omnes Capital, Sham Innovation Santé, Bernard Chauvin and CEA Investissement.
Who are EyeTechCare's competitors?
Competitors of EyeTechCare include AcuFocus, AlterG, Mercator MedSystems, AqueSys, Xlumena and 11 more.
Compare EyeTechCare to Competitors
NovaLign Orthopaedics, formerly known as OsteoLign, is developing a minimally invasive solution for long bone fractures.
Magneceutical Health is in the Complementary and Alternative Medicine market, and is dedicated to helping people improve their health and wellness by enhancing relaxation through the use of natural and holistic magnetic fields.
Myconostica Ltd develops and supplies molecular diagnostic products to aid rapid and accurate diagnosis of life-threatening invasive fungal infections. nnTraditional methods for the detection of fungal pathogens, such as culture and microscopy, are well-documented as being relatively insensitive and slow. Myconostica will use advances in molecular techniques, such as Real-Time PCR, to develop a range of assays for the rapid, accurate and sensitive detection of fungi such as Aspergillus spp., Pneumocystis jirovecii and Candida spp. Evidence shows that an early diagnosis of invasive fungal infection aims to improve the chance of survival. Tests provided by Myconostica will aim to allow healthcare professionals to rapidly identify those patients infected by invasive fungal pathogens thus enabling clinicians to prescribe appropriate drug therapy. Early identification of disease aims to reduce the patient's exposure to inappropriate drug treatments, aims to improve patient outcomes and aims to reduce the hospitalisation and treatment costs associated with invasive fungal disease. The company are a spin-out company of the University of Manchester, and a Partner Company of Amphion Innovations plc. (Amphion, AIM: AMP, develops and operates companies in the life sciences and technology sectors). n
Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.
Catheter Connections develops vascular access products that can help protect patients from life-threatening infections during infusion therapy. The company's flagship product, DualCap, a sterile, single-use device containing two disinfecting caps - one for the IV catheter needleless luer access valve (also known as the needleless injection site, port or valve) and one for the male luer connector at the end of the IV tubing - is an FDA-cleared device for disinfection and protection of both the IV catheter needleless luer access valve and the male luer connector at the end of the IV tubing. DualCap helps to prevent intraluminal contamination, the most common way IV connectors contribute to infections in long-term catheter use.
Realistic Eye aims to provide a more natural appearance for the 750,000 patients in the US with an artificial eye that does not dilate and therefore appears unnatural. RealisticEye achieves these results by introducing a dilating artificial eye.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.